Inflexion to acquire Sunovion Pharmaceuticals Europe

Japan-headquartered Sumitomo Dainippon is listed on the Tokyo stock exchange and said in a statement that Inflexion is to wholly acquire the shares in SPE from Sunovion Pharmaceuticals.

US-based Sunovion Pharmaceuticals has 1,620 employees and focuses on the treatment of central nervous system and respiratory diseases.

According to the same statement, SPE and Sumitomo Dainippon have signed a license and supply agreement for SPE's core Latuda product, meaning that this can continue to be marketed in Europe via SPE's existing structures.

Sumitomo Dainippon intends to continue its direct sales in Japan, China, Asia and North America.

Inflexion is currently deploying equity via funds including Inflexion Buyout Fund V, which held a final close in May 2018 on GBP 1.25bn.

The GP launched its sixth buyout fund in March 2021 with a target of GBP 2bn, according to Unquote Data.

Inflexion manages additional strategies including its minority-investments-focused Partnership Funds, as well as its Enterprise Funds, which target lower-mid-market businesses in the UK.

The GP's previous pharmaceutical sector investments include oral liquid medicines producer Rosemont Pharmaceuticals. The GP acquired the company in a GBP 156m buyout from trade player Perrigo in June 2020, investing via Inflexion Buyout V.

Company
Formed in 1997, Sunovion Pharmaceuticals Europe focuses on the development and commercialisation of treatments for serious medical conditions. Its flagship product is Latuda (lurasidone hydrochloride), which is used to treat schizophrenia. The company is headquartered in London and posts revenues of USD 28m, with 29 employees.

People
Inflexion – Simon Turner, John Hartz (managing partners).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• UK / Ireland
• Healthcare
• Carve-out
• United Kingdom
• Inflexion Private Equity